Duration of adjuvant therapy for stage III colon cancer: No longer one size fits all

[摘要] In 1990, a National Institute of Health consensus conference concluded that adjuvant chemotherapy should be recommended to patients with stage III colon cancer after surgical resection to reduce the risk of recurrence and improve survival.1 The initial trials that led to this conclusion tested 12 months of adjuvant fluoropyrimidine-based (either intravenous 5-FU or oral capecitabine) therapies; however, at least three trials demonstrated that six months of therapy was non-inferior to 12months.24

[学科分类] 外科医学